INNV - Comprehensive Filing Intelligence

FYNone•10-Q•Filed Feb 3, 2026

4.0/10

Filing Health:CAUTION

Notable concerns that warrant closer review

Executive Summary

Revenue growth is strong, driven by both increased capitation rates and higher member months.. Cost of care is increasing due to higher wages, pharmacy services transition, and contract transportation costs.. Significant DOJ investigation into False Claims Act violations with unestimatable potential losses.. Total revenues for PACE segment increased to $475.6M from $0.3M in the prior year's comparable period (likely due to full consolidation of prior year's 'All Other' segment).

Top Concerns

!Management expresses mixed confidence, highlighting both operational initiatives to offset rising costs and significant risks from labor shortages and regulatory changes.
!SBC expense decreased significantly YoY, but remains elevated relative to revenue.
!Significant concentration in Medicaid receivables (94%) creates potential collection risk.
!Significant DOJ investigation into False Claims Act violations with unestimatable potential losses.
!Ongoing arbitration with former pharmacy vendor for breach of contract, with unestimatable losses.

Top Positives

+Revenue growth is strong, driven by both increased capitation rates and higher member months.

Analysis Dimensions

Our 5-pass AI analysis examines this filing across multiple dimensions. Each dimension score is derived from direct analysis of SEC filing text.

Narrative Intelligence

7.0/10

Management tone is balanced with focus on increase in member months.

Full analysis includes: tone changes vs prior quarter, margin driver breakdown, forward guidance analysis, strategic priorities.

Accounting Quality

6.0/10

Earnings quality shows moderate accounting practices.

Full analysis includes: reserve and allowance changes, non-recurring item analysis, stock-based compensation impact, disclosure concerns.

Hidden Liabilities

Off-balance sheet risk is high.

Full analysis includes: cloud and purchase commitments, VIE/SPE exposure, covenant compliance status, refinancing risk assessment.

Risk Landscape

3.0/10

Overall risk profile shows regulatory and compliance risks as primary concern.

Full analysis includes: 8 risk categories with severity, new vs escalated risks, management response assessment, risk trend analysis.

Segment Performance

6.0/10

Segment health analysis.

Full analysis includes: segment-by-segment revenue breakdown, geographic concentration risk, customer concentration analysis, segment margin trends.